OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis

Pharmacogenetics and Genomics

Volumn 23, Issue 7, 2013, Pages 355-364

  Tamraza, Bani ^a   Fukushima, Hisayo ^a   Wolfe, Alan R ^a   Kaspera, Rudiger ^g   Totah, Rheem A ^g   Floyd, James S ^c,d   Ma, Benjamin ^a   Chu, Catherine ^a   Marciante, Kristin D ^c,d   Heckbert, Susan R ^c,e,h   Psaty, Bruce M ^c,d,e,f,h   Kroetz, Deanna L ^a   Kwok, Pui Yan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Cardiovascular Health Research Unit   (United States)

^d University of Medicine   (United States)

^e AVR: Department of Epidemiology   (United States)

^f Departments of Health Services   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Cerivastatin; Clopidogrel; Oatp1B1; Rhabdomyolysis

Indexed keywords

AMLODIPINE; CELECOXIB; CERIVASTATIN; CLOPIDOGREL; DILTIAZEM; GLIBENCLAMIDE; IRBESARTAN; LANSOPRAZOLE; MONTELUKAST; ORGANIC ANION TRANSPORTER 2; PIOGLITAZONE; RIFAMPICIN; ROFECOXIB; THIOLACTONE; VERAPAMIL;

ARTICLE; DRUG INDUCED DISEASE; DRUG SCREENING; GENE INTERACTION; GENE SEQUENCE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHABDOMYOLYSIS;

EID: 84879168884     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283620c3b     Document Type: Article

References (43)

1. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681-1690.
2. Omar MA, Wilson JP, TS Cox. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35:1096-1107.
3. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35:908-917.
4. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004; 13:417-426.
5. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy-a genome wide study. N Engl J Med 2008; 359:789-799.
6. Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011; 21:163-242.
7. Floyd JS, Kaspera R, Marciante KD,Weiss NS, Heckbert SR, Lumley T, et al. A screening study of drug-drug interactions in cerivastatin users: An adverse effect of clopidogrel. Clin Pharmacol Ther 2012; 91:896-904.
8. Kaspera R, Naraharisetti SB, Tamraz B, Sahele T, Cheesman MJ, Kwok PY, et al. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis. Pharmacogenet Genomics 2010; 20:619-629.
9. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCT method. Methods 2001; 25:402-408.
10. Ozaki H, Ishikawa CT, Ishii T, Toyoda A, Murano T, Miyashita Y, Shirai K. Clearance rates of cerivastatin metabolites in a patient with cerivastatininduced rhabdomyolysis. J Clin Pharm Ther 2005; 30:189-192.
11. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72:685-691.
12. Scheet P, Stephens M. A Fast and flexible statistical model for large-scale population genotype data: Applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet 2006; 78:629-644.
13. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9:215-236.
14. Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 2008; 36:663-669.
15. Food and Drug Administration-Center for Drug Evaluation and Research. Guidance for industry: Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. Maryland, USA: Food and Drug Administration-Center for Drug Evaluation and Research; 2012.
16. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008; 9:19-33.
17. Brunton L, Lazo J, Parker K. Goodman and Gilman the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006.
18. Muck W, Ritter W, Ochmann K, Unger S, Ahr G,Wingender W, Kuhlmann J. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 1997; 35:255-260.
19. Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, Hirschhauser C, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17:110-116.
20. Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005; 45:68-78.
21. Barroso EC, Pinheiro VG, Façanha MC, Carvalho MR, Moura ME, Campelo CL, et al. Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am J Trop Med Hyg 2009; 81:322-329.
22. Jindal C, Kumar S, Choudhari G, Goel H, Mittal B. Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A >G) & susceptibility in gallstone disease. Indian J Med Res 2009; 129:170-175.
23. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005; 15:513-522.
24. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007; 82:726-733.
25. Chung J-Y, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2005; 78:342-350.
26. Pasanen M, Neuvonen M, Neuvonen P, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16:873-879.
27. Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 2006; 24:239-247.
28. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73:554-565.
29. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75:415-421.
30. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14:429-440.
31. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lutjohann D, et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics 2005; 15:303-309.
32. Liao M, Raczynski AR, Chen M, Chuang BC, Zhu Q, Shipman R, et al. Inhibition of hepatic organic anion-transporting polypeptide by RNA interference in sandwich-cultured human hepatocytes: An in vitro model to assess transporter-mediated drug-drug interactions. Drug Metab Dispos 2010; 38:1612-1622.
33. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999; 62:25-31.
34. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 2001; 46:89-102.
35. Muck W, Ochmann K, Mazzu A, Lettieri J. Biopharmaceutical profile of cerivastatin: A novel HMG-CoA reductase inhibitor. J Int Med Res 1999; 27:107-114.
36. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 2011; 90:575-581.
37. Anderson CD, Biffi A, Greenberg SM, Rosand J. Personalized approaches to clopidogrel therapy: Are we there yet? Stroke 2010; 41:2997-3002.
38. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57:1251-1263.
39. Bhindi R, Ormerod O, Newton J, Banning AP, Testa L. Interaction between statins and clopidogrel: Is there anything clinically relevant? Q J Med 2008; 101:915-925.
40. Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 2008; 28:1483-1494.
41. Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH. Organic anion-transporting polypeptide 1B1 mediates transport of gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos 2009; 37:917-923.
42. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006; 34:1229-1236.
43. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, et al. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: Implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 2004; 32:291-294.